Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load

Conditions:   HIV Infections;   Fatty Liver Disease Interventions:   Drug: Dolutegravir (DTG) 50 mg/day + Rilpivirine (RPV) 25mg per day;   Drug: Tenofovir disoproxil fumarate (TDF) 245 mg per day or Tenofovir alafenamide (TAF) 25 mg per day + Emtricitabine (FTC) 200 mg per day + Rilpivirine 25 mg per day;   Drug: Continue with their previous treatment. Any pre vious HAART that does not contain Rilpivirine. Sponsor:   Fundacion SEIMC-GESIDA Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials